VYNE Therapeutics selects lead candidate for immuno-inflammatory treatment program
VYNE Therapeutics (NASDAQ:VYNE) has selected a lead candidate for its oral BD2-selective bromodomain
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial